Vol. 13. Núm. 17.
Páginas 949-956 (Octubre 2020)

Actualización
Estrategia terapéutica en el paciente diabético (II). Hipoglucemiantes orales. Consejos al paciente

Therapeutic strategy in diabetic patient (II). Oral lipid-lowering drugs. Advices to the patient

E. Lorenzo HernándezP. Gallardo JiménezJ.J. Mancebo Sevilla
Doi : https://10.1016/j.med.2020.09.020
Opciones
Resumen

Junto a los cambios en el estilo de vida, el tratamiento inicial en la mayoría de los pacientes con diabetes mellitus tipo 2 son las terapias no insulínicas. Dentro de ellas, disponemos actualmente de ocho grupos farmacológicos con diferentes mecanismos de acción, ventajas e inconvenientes, lo que nos permite individualizar el tratamiento para cada paciente en función de sus características. Metformina continúa siendo el tratamiento inicial de elección en los pacientes con diabetes tipo 2 y a ella se añadirán un segundo o tercer fármaco en caso necesario para alcanzar los objetivos glucémicos antes de plantear administrar insulina. La decisión sobre el fármaco a elegir como segundo escalón deberá basarse fundamentalmente en los antecedentes cardiovasculares del paciente, el riesgo de hipoglucemias y la presencia de obesidad o fragilidad.

Palabras clave
Diabetes mellitus tipo 2
Hipoglucemiantes orales
Terapia combinada
Efectos secundarios
Abstract

Oral non-insulin therapies in type 2 diabetic patients are, together with lifestyle changes, the first-line treatment. Eight pharmacological groups (with its action mechanism, advantages and disadvantages) are currently available; thus, according with patient features, treatment may be individualized. Metformin remains the initial treatment of choice in patients with type 2 diabetes. Before to establish insulin therapy, a second or third drug will be added if it is necessary. Second drug choice is based fundamentally on patient's cardiovascular history, the risk of hypoglycemia and the presence of obesity or frailty.

Keywords
Type 2 diabetes mellitus
Oral non-insulin therapies
Combined therapy
Adverse effects

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
M.V.
202010230702210111
Romero Rey, J.M. Álvarez Gutiérrez, E. Gómez Lucas, J.J. Lozano García.
Manejo terapéutico de la hiperglucemia en la diabetes tipo 2.
Antidiabéticos orales. Medicine., (2012), 11 pp. 1073-1081
[2]
M.J.
202010230702210112
202010230702210113
Davies, D.A. D’Alessio, J. Fradkin, W.N. Kernan, C. Mathieu, G. Mingrone, et al.
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care., (2018), 41 pp. 2669-2701
[3]
202010230702210114
202010230702210115
American Diabetes Association.
Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020.
Diabetes Care., (2020), 43Suppl1 pp. S98-S110
[4]
J.B.
202010230702210116
202010230702210117
Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu, et al.
2019 update to: management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetes Care., (2020), 43 pp. 487-493
[5]
D.S.
202010230702210118
Shyangdan, P. Royle, C. Clar, P. Sharma, N. Waugh, A. Snaith.
Glucagon-like peptide analogues for type 2 diabetes mellitus.
Cochrane Database Syst Rev., (2011), pp. CD006423
[6]
C.H.
202010230702210119
Koliaki, J. Doupis.
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 Diabetes mellitus.
Diabetes Ther., (2011), 2 pp. 101-121
[7]
Z.Z.
2020102307022101110
Htike, F. Zaccardi, D. Papamargaritis, D.R. Webb, K. Khunti, M.J. Davies.
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Diabetes Obes Metab., (2017), 19 pp. 524
[8]
Y.
2020102307022101111
Fujita, N. Inagaki.
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action.
J Diabetes Invest., (2014), 5 pp. 265-275
[9]
J.J.
2020102307022101112
Alemán, S. Artola, L. Ávila, J. Barrot, L. Barutell, B. Benito, et al.
Guía de diabetes tipo 2 para clínicos: recomendaciones de la redGDPS.
Fundación redGDPS, (2018), pp. 1-264
[10]
S.P.
2020102307022101113
2020102307022101114
Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. Jódar, L.A. Leiter, et al.
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
N Engl J Med., (2016), 375 pp. 1834-1844
[11]
S.P.
2020102307022101115
2020102307022101116
Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F.E. Mann, M.A. Nauck, et al.
Liraglutide and cardiovascular outcomes in type 2 diabetes.
N Engl J Med., (2016), 375 pp. 311-322
[12]
R.
2020102307022101117
2020102307022101118
Gómez-Huelgas, F. Gómez-Peralta, L. Rodríguez Mañas, F. Formiga, M. Puig-Domingo, J.J. Mediavilla-Bravo, et al.
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano.
Rev Clin Esp., (2018), 218 pp. 74-88
[13]
J.B.
2020102307022101119
2020102307022101120
Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, et al.
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.
N Engl J Med., (2015), 373 pp. 232-242
[14]
W.B.
2020102307022101121
White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, et al.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
N Engl J Med., (2013), 369 pp. 1327-1335
[15]
B.M.
2020102307022101122
2020102307022101123
Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, et al.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
N Engl J Med., (2013), 369 pp. 1317-1326
[16]
B.
2020102307022101124
2020102307022101125
Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, et al.
Empagliflozin cardiovascular outcomes, and mortality in type 2 diabetes.
N Engl J Med., (2015), 373 pp. 2117-2128
[17]
B.
2020102307022101126
2020102307022101127
Neal, V. Perkovic, D.R. Matthews.
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
N Engl J Med., (2017), 377 pp. 644-657
[18]
S.D.
2020102307022101128
2020102307022101129
Wiviott, I. Raz, M.P. Bonaca, O. Monsezon, E.T. Kato, A. Cahn, et al.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med., (2019), 380 pp. 347-357
[19]
V.
2020102307022101130
Perkovic, M.J. Jardine, B. Neal, S. Bompoint, H.J.L. Heerspink, D.M. Charytan, et al.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
N Engl J Med., (2019), 380 pp. 2295-2306
[20]
R.
2020102307022101131
2020102307022101132
Reyes-García, O. Moreno-Pérez, C. Tejera-Pérez, D. Fernández-García, V. Bellido-Castañeda, M. López de la Torre-Casares, et al.
Documento de abordaje integral de la diabetes tipo 2. Grupo de trabajo de Diabetes mellitus de la Sociedad Española de Endocrinología.
Endocrinol Diabetes Nutr., (2018), 66 pp. 443-458
[21]
F.
2020102307022101133
Gómez-Peralta, C. Abreu, A. Lecube, D. Bellido, A. Soto, C. Morales, et al.
Practical approach to initiating SGLT2 inhibitors in type 2 diabetes.
Diabetes Therapy., (2017), 8 pp. 953-962
[22]
D.R.
2020102307022101134
2020102307022101135
Matthews, P.M. Paldanius, P. Proot, Y. Chiang, M. Stumvoll, S. Del Prato, VERIFY study group.
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Lancet., (2019), 394 pp. 1519-1529
[23]
E.
2020102307022101136
Ganado, I. Garay, L. Vega.
Tema 4, antidiabéticos orales. Curso básico de diabetes.
Farmacia Comunitaria., (2016), 30 pp. 23-30
[24]
V.R.
2020102307022101137
Aroda, S.L. Edelstein, R.B. Goldberg, W.C. Knowler, S.M. Marcovina, T.J. Orchard, et al.
Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study.
J Clin Endocrinol Metab., (2016), 101 pp. 1754-1761